Navigation Links
FDA Determines VYVANSE(R) was Properly Granted Five-Year Market Exclusivity
Date:10/26/2009

DUBLIN, October 26 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R). The five-year exclusivity period for VYVANSE expires on February 23, 2012. VYVANSE is covered by United States patents which remain in effect until June 29, 2023.

On February 23, 2007, after reviewing the requisite clinical studies submitted on behalf of VYVANSE, the FDA determined that VYVANSE qualified as a NCE and was entitled to five-year market exclusivity. The FDA therefore appropriately refused to file the Abbreviated New Drug Application submitted by Actavis Elizabeth, LLC (Actavis) for generic lisdexamfetamine dimesylate in January 2009. On February 24, 2009, Actavis sued the FDA in the District Court of the District of Columbia challenging the NCE decision. On April 13, 2009, the FDA opened a public docket to consider Actavis's challenge to the FDA's regulations governing NCE exclusivity and the corresponding award of exclusivity to VYVANSE. The court case was stayed pending the outcome of this FDA review.

Notes to editors

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
2. Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
3. New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)
4. Dallas Researchers Find Compression Stockings Improperly Used
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
7. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
8. Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery
9. Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
10. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
11. Emphasys Medical Granted Expedited Review From FDA for Zephyr(R) Endobronchial Valve
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... , Sept. 20, 2014 /CNW/ - The issue: Mylan Pharmaceuticals ... all lots of its Mylan-Nitro Spray 0.4 mg/metered dose due ... of the pump component. A missing "dip ... nitroglycerin to the patient. This defect may lead patients to ... are unable to access it. Not receiving nitroglycerin could place ...
(Date:9/19/2014)... N.C. , Sept. 19, 2014 ... in forging relationships with key opinion leaders (KOLs) ... and competition. Despite the critical nature of the ... many challenges, including altering the landscape for creating ... According to research, the oversight responsibility for ...
(Date:9/19/2014)... 2014 Harwood Feffer LLP ( www.hfesq.com ) ... of PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: ... breached its fiduciary duties to shareholders or violated the ... the Company disclosed: "On September 11, 2014, [PDL] was ... & Young LLP ("EY"), that it was resigning effective ...
Breaking Medicine Technology:Advisory - Mylan Pharmaceuticals recalling nitroglycerin spray due to defective pump 2Role of Medical Science Liaisons Shifting in Healthcare Industry 2Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2
... June 16, 2011 The largest human dermal allograft available ... will be introduced at the AWR meeting here this week. ... is introducing FlexHD acellular hydrated dermal matrix 20 ... cm x 25 cm grafts. FlexHD ...
... our scope of services, Shenzhen Wuzhou Changlian International Trading ... with a city hospital in the Southeast of Africa soon, ... equipment. Wuzhou Changlian has offered specialty body-care products ... which puts a focus on meeting local people,s needs and ...
Cached Medicine Technology:Largest Acellular Dermal Allografts Available for Abdominal Wall Reconstruction Introduced at AWR 2011 2Shenzhen Wuzhou Changlian International Trading Co. Establishes Relationship with Hospital in Africa 2
(Date:9/21/2014)... (PRWEB) September 21, 2014 “Cluster headaches ... so intense and difficult to resolve,” said Steve Young ... can't think of a pain that is more intense.” ... suffers from cluster headaches, or migraines, that medical research ... the serotonin system,” he added. , Serotonin (5-HT, 5-hydroxytryptamine) ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 Recently, BambooIndustry.com, ... a special offer for its bamboo panels ( http://www.bambooindustry.com/products/bamboo-panel/ ... the market; all of them are available at discounted ... , The company’s discounted bamboo panels are ... made of quality materials. Each of them is finely ...
(Date:9/21/2014)... Aliso Viejo, California (PRWEB) September 21, 2014 ... Pro X plugins have announced a new transition ... , “Transpack Vol. 3 delivers high quality transitions that ... video project,” said Christina Austin, CEO of Pixel Film ... Vol. 3 is a definite game changer.” , Transpack ...
(Date:9/21/2014)... Faculty and staff at Garrison Forest School (GFS), an ... Md., kicked off the academic year by taking a big ... first independent school to receive the bands— which calculate activity ... as part of a pilot program with Charm City ... The Vivofit bands are just one tool in a new ...
(Date:9/21/2014)... 2014 C8 lawsuits move forward in ... the list of 20 possible C8 lawsuits selected ... six, reports Wright & Schulte LLC. Court records show ... 2500 C8 lawsuits filed that represent individuals who purportedly ... a result of being exposed to water contaminated by ...
Breaking Medicine News(10 mins):Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:Discounted Bamboo Panels For Sale At BambooIndustry.com 2Health News:Pixel Film Studios Released Transpack Vol. 3 Plugin Exclusively for Final Cut Pro X 2Health News:Garrison Forest School Leader in Independent School Wellness Programs 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 3Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 4
... ... by the U.S. Food and Drug Administration (FDA), Immunovative Therapies, Ltd. ... vaccine product for the treatment of advanced metastatic solid tumors will begin ... inside the body by combining the experimental AlloStimTM drug with the killing ...
... ... software for long-term care will present a technology and admissions educational session for THCA ... Atlanta, ... Web-based admissions for long-term care providers, announced today that it will present a session ...
... ... ,fight the bite, from America,s most unwanted species; the aggressive, disease-carrying, Asian Tiger mosquito ... Mega-Catch™ mosquito traps. , ... Auckland, NZ (PRWEB) August 14, 2009 -- The patent-pending, Mega-Catch™ 3000 combo lure ...
... ... 40% of women find holidays more stressful than they should be. A male,s ... is their biggest nightmare. Under 30s are the most stressed on holiday. , ... Cardiff, UK (PRWEB) August 14, 2009 ...
... , , , SACRAMENTO, ... contribution of up to $81.4 million to the Healthy Families Program today ... at risk of losing coverage due to the state,s fiscal crisis. The ... used to cover children ages 0-5 through June 2010. , , ...
... find types of hormones used raise or lower clot ... composition of a woman,s contraceptive pill influences her risk ... European researchers say. , Scientists have long known that ... progestogen, increase the likelihood of deep vein thrombosis of ...
Cached Medicine News:Health News:CryoStim™ Cancer Treatment to Begin FDA Clinical Trials September 1, 2009 2Health News:CryoStim™ Cancer Treatment to Begin FDA Clinical Trials September 1, 2009 3Health News:Patient Placement Systems Presents a Session at the THCA 2009 Annual Convention 2Health News:Patient Placement Systems Presents a Session at the THCA 2009 Annual Convention 3Health News:Mega-Catch™ 3000 Combination Lure Attracts Asian Tiger Mosquitoes (Aedes Albopictus) 2Health News:Mega-Catch™ 3000 Combination Lure Attracts Asian Tiger Mosquitoes (Aedes Albopictus) 3Health News:Spain Has The 'Stress' Factor, According to Confused.com 2Health News:Spain Has The 'Stress' Factor, According to Confused.com 3Health News:First 5 California Approves $81.4 Million Contribution to Help Restore Healthy Families Program's Viability 2Health News:Some Birth Control Pills Safer Than Others 2Health News:Some Birth Control Pills Safer Than Others 3
UROSKOP Access, the dedicated urodiagnostic table with truly unrestricted patient access optimizes nearly all diagnostic and interventional procedures....
Drew Scientific has been making leading edge and top quality CBC systems for over 15 years.,The Excell 16/18 offers a reliable alternative for a 3 part differential....
... therapeutic, expandable turning surface for the BariMaxx™ ... Prevention and treatment of pressure ulcers, Large ... patients using a statuc mattress that would ... whose body weight and size pose a ...
... The BariMaxx™ is a full-featured healthcare bed ... for the care and management of larger ... to 1000 lbs. ,Large patients at risk ... in excess of 1000 lbs. (including accessories), ...
Medicine Products: